Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH dr...
Gespeichert in:
| Veröffentlicht in: | Vascular pharmacology 2024-06, Vol.155, p.107371, Article 107371 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 107371 |
| container_title | Vascular pharmacology |
| container_volume | 155 |
| creator | Morales-Cano, Daniel Barreira, Bianca Callejo, María Olivencia, Miguel A. Ferruelo, Antonio Milara, Javier Lorente, José Ángel Moreno, Laura Cogolludo, Ángel Perez-Vizcaino, Francisco |
| description | An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells. |
| doi_str_mv | 10.1016/j.vph.2024.107371 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3037398920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S153718912400096X</els_id><sourcerecordid>3037398920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-d48cbd968630e4a681fcb4a1326dd92fa84aa16121cf713f187b5e699fe212d3</originalsourceid><addsrcrecordid>eNp9UU1v3CAURFWj5vMH9FJxzMUbMF4M7Sla5UuKlEvuiIVHl5VtXMBW9mf0H5fdTXLsiXmPeSPNDELfKVlQQvnNdjGPm0VN6qbMLWvpF3RGRSsrxhv5teAlaysqJD1F5yltCaFCcPkNnTKxlJIt2zP0dxX6UUed_QxYD7rbJZ9wcAVnP8bQeQefvxbPOgXrO51DxOAcmHwg2zj9TtiV5Th1fRh03OHNboSYYUg-DD_x3dsBFhk_4NnnGHDKk93tx6KfDuqbqdfDJTpxuktw9f5eoNf7u9fVY_X88vC0un2uDGtErmwjzNpKLjgj0GguqDPrRlNWc2tl7bRotKac1tS4ljJXclkvgUvpoKa1ZRfo-ihbTP6ZIGXV-2Sg6_QAYUqKEdYyKWRNCpUeqSaGlCI4NUbfF4-KErUvQm1VKULti1DHIsrNj3f5ad2D_bz4SL4Qfh0JUDzOHqJKxsNgwPpYYlU2-P_I_wMgW50F</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3037398920</pqid></control><display><type>article</type><title>Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Morales-Cano, Daniel ; Barreira, Bianca ; Callejo, María ; Olivencia, Miguel A. ; Ferruelo, Antonio ; Milara, Javier ; Lorente, José Ángel ; Moreno, Laura ; Cogolludo, Ángel ; Perez-Vizcaino, Francisco</creator><creatorcontrib>Morales-Cano, Daniel ; Barreira, Bianca ; Callejo, María ; Olivencia, Miguel A. ; Ferruelo, Antonio ; Milara, Javier ; Lorente, José Ángel ; Moreno, Laura ; Cogolludo, Ángel ; Perez-Vizcaino, Francisco</creatorcontrib><description>An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.</description><identifier>ISSN: 1537-1891</identifier><identifier>ISSN: 1879-3649</identifier><identifier>EISSN: 1879-3649</identifier><identifier>DOI: 10.1016/j.vph.2024.107371</identifier><identifier>PMID: 38599357</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Proliferation ; Pulmonary hypertension ; Vascular smooth muscle ; Vasodilation</subject><ispartof>Vascular pharmacology, 2024-06, Vol.155, p.107371, Article 107371</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024. Published by Elsevier Inc.</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c348t-d48cbd968630e4a681fcb4a1326dd92fa84aa16121cf713f187b5e699fe212d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vph.2024.107371$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38599357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morales-Cano, Daniel</creatorcontrib><creatorcontrib>Barreira, Bianca</creatorcontrib><creatorcontrib>Callejo, María</creatorcontrib><creatorcontrib>Olivencia, Miguel A.</creatorcontrib><creatorcontrib>Ferruelo, Antonio</creatorcontrib><creatorcontrib>Milara, Javier</creatorcontrib><creatorcontrib>Lorente, José Ángel</creatorcontrib><creatorcontrib>Moreno, Laura</creatorcontrib><creatorcontrib>Cogolludo, Ángel</creatorcontrib><creatorcontrib>Perez-Vizcaino, Francisco</creatorcontrib><title>Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human</title><title>Vascular pharmacology</title><addtitle>Vascul Pharmacol</addtitle><description>An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.</description><subject>Proliferation</subject><subject>Pulmonary hypertension</subject><subject>Vascular smooth muscle</subject><subject>Vasodilation</subject><issn>1537-1891</issn><issn>1879-3649</issn><issn>1879-3649</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UU1v3CAURFWj5vMH9FJxzMUbMF4M7Sla5UuKlEvuiIVHl5VtXMBW9mf0H5fdTXLsiXmPeSPNDELfKVlQQvnNdjGPm0VN6qbMLWvpF3RGRSsrxhv5teAlaysqJD1F5yltCaFCcPkNnTKxlJIt2zP0dxX6UUed_QxYD7rbJZ9wcAVnP8bQeQefvxbPOgXrO51DxOAcmHwg2zj9TtiV5Th1fRh03OHNboSYYUg-DD_x3dsBFhk_4NnnGHDKk93tx6KfDuqbqdfDJTpxuktw9f5eoNf7u9fVY_X88vC0un2uDGtErmwjzNpKLjgj0GguqDPrRlNWc2tl7bRotKac1tS4ljJXclkvgUvpoKa1ZRfo-ihbTP6ZIGXV-2Sg6_QAYUqKEdYyKWRNCpUeqSaGlCI4NUbfF4-KErUvQm1VKULti1DHIsrNj3f5ad2D_bz4SL4Qfh0JUDzOHqJKxsNgwPpYYlU2-P_I_wMgW50F</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Morales-Cano, Daniel</creator><creator>Barreira, Bianca</creator><creator>Callejo, María</creator><creator>Olivencia, Miguel A.</creator><creator>Ferruelo, Antonio</creator><creator>Milara, Javier</creator><creator>Lorente, José Ángel</creator><creator>Moreno, Laura</creator><creator>Cogolludo, Ángel</creator><creator>Perez-Vizcaino, Francisco</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human</title><author>Morales-Cano, Daniel ; Barreira, Bianca ; Callejo, María ; Olivencia, Miguel A. ; Ferruelo, Antonio ; Milara, Javier ; Lorente, José Ángel ; Moreno, Laura ; Cogolludo, Ángel ; Perez-Vizcaino, Francisco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-d48cbd968630e4a681fcb4a1326dd92fa84aa16121cf713f187b5e699fe212d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Proliferation</topic><topic>Pulmonary hypertension</topic><topic>Vascular smooth muscle</topic><topic>Vasodilation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morales-Cano, Daniel</creatorcontrib><creatorcontrib>Barreira, Bianca</creatorcontrib><creatorcontrib>Callejo, María</creatorcontrib><creatorcontrib>Olivencia, Miguel A.</creatorcontrib><creatorcontrib>Ferruelo, Antonio</creatorcontrib><creatorcontrib>Milara, Javier</creatorcontrib><creatorcontrib>Lorente, José Ángel</creatorcontrib><creatorcontrib>Moreno, Laura</creatorcontrib><creatorcontrib>Cogolludo, Ángel</creatorcontrib><creatorcontrib>Perez-Vizcaino, Francisco</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morales-Cano, Daniel</au><au>Barreira, Bianca</au><au>Callejo, María</au><au>Olivencia, Miguel A.</au><au>Ferruelo, Antonio</au><au>Milara, Javier</au><au>Lorente, José Ángel</au><au>Moreno, Laura</au><au>Cogolludo, Ángel</au><au>Perez-Vizcaino, Francisco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human</atitle><jtitle>Vascular pharmacology</jtitle><addtitle>Vascul Pharmacol</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>155</volume><spage>107371</spage><pages>107371-</pages><artnum>107371</artnum><issn>1537-1891</issn><issn>1879-3649</issn><eissn>1879-3649</eissn><abstract>An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38599357</pmid><doi>10.1016/j.vph.2024.107371</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1537-1891 |
| ispartof | Vascular pharmacology, 2024-06, Vol.155, p.107371, Article 107371 |
| issn | 1537-1891 1879-3649 1879-3649 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3037398920 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Proliferation Pulmonary hypertension Vascular smooth muscle Vasodilation |
| title | Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A08%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20analysis%20of%20antiproliferative%20and%20vasodilator%20effects%20of%20drugs%20for%20pulmonary%20hypertension:%20Extensive%20in%20vitro%20study%20in%20rats%20and%20human&rft.jtitle=Vascular%20pharmacology&rft.au=Morales-Cano,%20Daniel&rft.date=2024-06-01&rft.volume=155&rft.spage=107371&rft.pages=107371-&rft.artnum=107371&rft.issn=1537-1891&rft.eissn=1879-3649&rft_id=info:doi/10.1016/j.vph.2024.107371&rft_dat=%3Cproquest_cross%3E3037398920%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3037398920&rft_id=info:pmid/38599357&rft_els_id=S153718912400096X&rfr_iscdi=true |